Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

In addition to ADCs, other types of highly potent biologics require specialized manufacturing skills.

Assessing Risk and Production of Potent Substances

Sandoz plans to strengthen its European antibiotics manufacturing network by expanding its production capabilities in Kundl, Austria, and Palafolls, Spain.

Sandoz to Expand Production Capabilities to Strengthen its European Antibiotics Manufacturing Network

Colorcon’s new suite will provide clients with capabilities to develop prototype tablets or capsule dosage forms when API quantity is limited or the API potency requires a higher level of protection.

Colorcon to Expand its Technical Capabilities with New Containment Suite at its Pennsylvania Headquarters

Applying a QbD approach helps address excipient variability and other quality features.

QbD Helps Evaluate Excipient Variability 

Topical drugs are attractive to patients, but these complex products pose challenges for formulators.

Balancing the Art and Science of Topical Drug Formulation

Without an independent approval pathway for novel excipients, true pharmaceutical innovation could be stymied.

Novel Excipients Needed More Than Ever Before

The company will expand the site to include six new containment isolators and a product development manufacturing laboratory.

Vectura to Incorporate HPAPI Capabilities into UK Facility 

Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.

HPAPI Complexity Prompts New Delivery Mechanisms

Construction on the workshop is currently underway with plans for it to be fully operational by the end of 2021.

Novasep to Invest $7.6 million to Expand API Manufacturing Workshop Capacity

Biological and analytical advances enable modern fermentation processes to deliver safe and effective next-generation medicines.

APIs and Excipients